Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary

Health Policy

Volumn 91, Issue 2, 2009, Pages 142-147

  Lexchin, Joel ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dosage forms; Drug costs; Drug industry; Formularies

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BENAZEPRIL; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CERIVASTATIN; CILAZAPRIL; ENALAPRIL; EPROSARTAN; FLUINDOSTATIN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; MEVINOLIN; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PRAVASTATIN; QUINAPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CANADA; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; TABLET;

AGED; COMMERCE; DOSAGE FORMS; FORMULARIES AS TOPIC; HEALTH EXPENDITURES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; ONTARIO; PHARMACEUTICAL PREPARATIONS;

EID: 67349110822     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.12.002     Document Type: Article

References (16)

1. Jönsson B. Flat or monotonic pricing of pharmaceuticals: practice and consequences. Health Economics in Prevention and Care 2 (2001) 104-112
2. Berndt E.R. Pharmaceuticals in U.S. health care: determinants of quantity and price. Journal of Economic Perspectives 16 (2002) 45-66
3. Canadian Institute for Health Information. Drug expenditure in Canada 1985 to 2006 (2007), CIHI, Ottawa
4. Federal/Provincial/Territorial Ministerial Task Force. National pharmaceuticals strategy progress report. Ottawa; 2006.
5. Patented Medicine Prices Review Board. Annual report 2007. Ottawa: PMPRB; 2008.
6. Lexchin J. Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. CMAJ 174 (2006) 1120-1121
7. Ministry of Health Ontario. Drug benefit formulary no. 34 (1994), Queen's Printer for Ontario, Toronto
8. In: Repchinsky C. (Ed). Compendium of pharmaceuticals and specialties 2007: The Canadian drug reference for health professionals (2007), Canadian Pharmacists Association, Ottawa
9. WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. Norwegian Institute of Public Health, http://www.whocc.no/atcddd/; 2005 [accessed 30.06.05].
10. In: Rossi S. (Ed). Australian medicines handbook (2007), Australian Medicines Handbook Pty Ltd., Adelaide
11. In: Gray J. (Ed). Therapeutic choices. 5th ed. (2007), Canadian Pharmacists Association, Ottawa
12. Cross J., Lee H., Westelinck A., Nelson J., Grudzinskas C., and Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiology and Drug Safety 11 (2002) 439-446
13. Allan G.M., Lexchin J., and Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Medicine 4 (2007) e283
14. Patented Medicine Prices Review Board. Inter-provincial prescription drug price comparison 1995/96-1999/00. Ottawa: Federal/Provincial/Territorial Working Group on Drug Prices; nd.
15. Ontario Ministry of Health. 2005/06 Report card for the Ontario Drug Benefit Program http://www.ontla.on.ca/library/repository/mon/16000/270771.pdf; 2006 [accessed 16.04.08].
16. Government of Canada. Patent act (R.S., 1985, c. P-4).